Table 1.

Potential targets and drugs against the interplay between cancer cells and adipocytes

Target	Agent	Mechanism	Anti-cancer effect	Reference
PPARγ	GW9662	Suppression of adipocyte differentiation	Inhibition of the anti-PD-L1 effect of adipocytes	[106]
adipogenesis	Sulforaphane	Suppression of adipocyte differentiation	Inhibition of the cancer promoting effect of adipocytes	[111]
β-adrenergic	Propranolol	Suppression of lypolysis in adipocytes	Inhibition of the EOC promoting effect of adipocytes	[15]
lipid droplet	Myricetin	Suppression of the lipid droplets accumulation	Inhibition of the EOC promoting effect of adipocytes	[15, 112]
β-oxidation	Trimetazidine	Inhibition of fatty acid oxidation	Inhibition of the EOC promoting effect of adipocytes	[15, 113]
CD36	Sulfo-N-succinimidyl oleate	Inhibition of fatty acid uptake of EOC cells	Inhibition of the EOC progression and metastasis induced by adipocytes	[114]
Leptin	pegylated leptin peptide receptor antagonist 2	Leptin antagonist	Inhibition of ovarian cancer peritoneal metastasis	[115]
IL-6	Tocilizumab	Monoclonal antibody against IL-6R	Enhancement of the immunity in patients with recurrent EOC	[116]
VEGF-A	Bevacizumab	Monoclonal antibody against VEGF-A	Improvement of the survival in patients with ovarian cancer	[81]